header logo image


Page 480«..1020..479480481482..490500..»

Investing in the vaccines of tomorrow: the case for biotechnology – Livewire Markets

June 27th, 2020 9:43 pm

Technology may typically be thought of in termsof computers and communications but its use inthe sphere of biotechnology is saving lives andchanging how we treat diseases. While investingin this area has obvious appeal from a social andmoral perspective, it can also be a highly lucrativespace as a growth investment in a portfolio.

Biotechnology is a sub-industry of the healthcaresector, which is typically divided into two spheres:

Biotechnology specifically refers to technologiesthat use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based onbiological and genetic information. The differenttypes of biotechnology include biological drugs,vaccines, immunotherapy, gene therapy, orphandrugs and genetic engineering.

While it may sound like a newer industry, biotechnology has a long rich history the creation ofpenicillin is in fact a form of biotechnology. Thecontinued improvements in technology over timehave also benefitted the biotechnology industry,enhancing the ability to access and use biologicalprocesses which we may not have even beenaware existed in the past. For example, DNAsequencing has revolutionised our ability to diagnose certain health concerns in individuals.Genome editing is a newer technology which maytransform how we treat or cure genetic diseases.

Demand is only likely to continue, not just on thebasis of the permanent need for treatments andvaccines for existing and yet to be identifieddiseases, but also because of the ability toimprove the way in which we treat. Imagine aworld where any illness you have can be treatedwith a drug specifically designed to work withyour genes and therefore minimise negativeside-effects and reduce recovery time? This is afuture that biotechnology is working towards.

It is no secret that biotechnology has experiencedextraordinary growth in recent times. Even in Australia, the fact that CSL Limited toppled Commonwealth Bank and BHP this year to become thelargest company by market capitalisation is anindication of the growing importance and value ofbiotechnology (1).

Biotechnology is predicted to be valued at morethan US$729bn by 2025, compared to US$295bntoday (2), and will continue to grow, driven by thegrowing global population and the need for affordable, effective treatments and vaccines to supporttreatment in the population.

Biotechnology will also be a beneficiary of population ageing, particularly in Western countries. Thereason for this is that an increase in the volume ofolder citizens is likely to have an accompanyingand proportional increase in the volume of age-related diseases such as cardiovascular disease,dementia or arthritis, all needing treatment (3).

Gilead is one example of a company with prospects in this space. Gilead is already well-knownfor its highly effective HIV treatments but is alsotargeting US and European approvals to market a drug called Filgotinib to treat rheumatoidarthritis (4).

In a demonstration of the growth in this industry,this year alone, 30-35 biotechnology companiesare anticipated to go public, raising approximatelyUS$3.5bn (5)

The COVID-19 pandemic may assist in accelerating the growth in biotechnology. Biotechnologycompanies have been at the forefront in seekingvaccines and cures for COVID-19. There arecurrently 11 potential COVID-19 vaccines in clinical evaluation (that is, undergoing testing) and afurther 128 in pre-clinical evaluation (6). Moderna isan example of a major biotechnology companyrunning clinical testing currently. It was the firstcompany to start human trials and anticipatesentering phase 3 trials with 30,000 participants byJuly (7).

The healthcare sector as a whole is likely to seegreater investment as a result of the COVID-19pandemic. For example, national health spendinggrowth in the US is expected to average 5.4%annually through 2028, reaching US$6tr a year (8).Biotechnology will also be a beneficiary of thisincreased investment.

Australian investors tend to have a concentrateddomestic exposure to biotechnology given thedominance of players such as CSL, Cochlear orResMed but may be missing the growth and diversification offered overseas. The US in particular ispositioned as the global centre of biotechnology.

The US biotechnology industry is valued at113.3bn (9), approximately 14x the size of the Australian biotechnology industry (10).

The reason for the US dominance in this field isdue in part to the world-renowned US Food & DrugAdministration (FDA) approval process and alsoto the size of its customer base.

Any companies seeking access to distribute theirproducts in the US market need to submit to FDAevaluation and in turn, many companies havesought to base themselves there for easieraccess to the process and for easier distributionand marketing to US consumers.

Australian investors can consider the US biotechnology industry as a diversification measure,along with exposure to a high growth segmentinternationally.

Biotechnology can be a high-risk industry, withhigh costs for drug development and high chances of failure. The rewards for successful trials canalso be immense.

To put this in perspective, in any given year, 54% ofclinical phase 3 trials typically fail for a range ofreasons (11), with average costs for developing adrug estimated at more than US2.1bn (12). The trialsand approval process can take years, often 10years or more, with less than 12% reachingapproved status with the FDA (13).

Biotech and healthcare companies then deriverevenue from approved products using patents,which last approximately 20 years from the dateof application (but also require maintenance feesand in some cases, can be extended) (14). Thismeans generic, cheaper versions from competitors cannot be sold in this period, allowing a company an effective monopoly over a particular formof treatment in that time. Of course, once thispatent expires, competitors can enter, so companies will continue research, development and testing on a permanent basis in the hope of findingthe next major treatment they can generaterevenue from.

Another source of return for this industry is from ahigh rate of merger and acquisition activity. Smaller and mid-size biotechnology companies areoften targets for larger firms, wanting to expandwith complementary capabilities they might notpreviously have had. Its a mutually beneficial relationship, providing smaller and mid-size companies with the capital they need to finance development and testing.

Mergers and acquisitions for biotechnology wasvalued at US$23bn in 2019 (15). Pre-COVID-19,activity was tipped to step up in activity for 2020,with oncology, cardiovascular/metabolic disease, immunology, infectious disease and centralnervous system disorders anticipated to benefit (16).

Investment and value from biotechnology isexpected to grow in coming years. While the trendalready existed due to continuous tech improvements and the needs of a growing population, theCOVID-19 pandemic has created a new spotlighton this area which may accelerate its growth.

While Australian investors are likely to already beexposed to this growth segment in the concentrated domestic market, they may be missingexposure to the US, which dominates the globalmarket for biotechnology.

There are a range of ways to access the biotechnology industry.Investors could consider direct shares in biotechnology companies or alternatively consider managed funds. Direct shares can be a high-riskapproach due to the high failure rates of drug testing and long periods of development (i.e., longperiods where there may be no or a limited returnon investment). Theres also the element ofchance has the investor picked the winner? Itcould take years to know.

Managed investments, be it an actively managedfund or passive options like ETFs, can assist inmanaging the risks by spreading it across a largernumber of companies. Investors could choose toinvest by taking a sector approach and investingin a fund focusing on broader healthcare, or lookat industry-specific options focusing on biotechnology. ETFS S&P Biotech ETF (ASX:CURE)is one such example that offers broad exposure toUS biotechnology.

ETFS S&P Biotech ETF (ASX:CURE),offers investors exposure to US biotechnology companies engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

For more information on investing in biotechnology please hit the 'CONTACT' button below.

Footnotes

Read this article:
Investing in the vaccines of tomorrow: the case for biotechnology - Livewire Markets

Read More...

Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today – The Motley Fool

June 27th, 2020 9:43 pm

What happened

The stocks of several biotechs focused on developing treatments and vaccines for COVID-19 jumped on Wednesday. Shares of Dynavax Technologies (NASDAQ:DVAX) were up 4% as of 3:13 p.m. EDT today after rising as much as 10.1% earlier in the day. Novavax (NASDAQ:NVAX) was up 13.4%, and shares of Vir Biotechnology (NASDAQ:VIR) were soaring 16.8% higher.

None of these companies reported news today. But the overall stock market fell on concerns about the increased number of COVID-19 cases in the U.S. This bad news translated to good news for Dynavax, Novavax, and Vir as investors scooped up shares of the key players in the fight against the coronavirus.

Image source: Getty Images.

Buying coronavirus-focused biotech stocks just because the pandemic appears to be worsening isn't a great idea without assessing the overall prospects for each individual stock. The dynamics are quite different for Dynavax, Novavax, and Vir.

Dynavax is the only one of the three to already have an approved product of any kind on the market. Its hepatitis B vaccine Heplisav-B generated $10.5 million in sales in the first quarter. The CpG 1018 adjuvant used in Heplisav-B is also being used in four COVID-19 vaccines, including ones developed by Chinese drugmakers Clover Biopharmaceuticals and Sinovac Biotech.

Novavax appears to be on track to win its first Food and Drug Administration approval, though. The company reported positive results in March from a late-stage study of flu vaccine NanoFlu. The vaccine could potentially generate peak sales in the ballpark of $1.7 billion if approved, according to one analyst's estimate. Novavax also has a promising COVID-19 vaccine in development that's in a phase 1/2 clinical trial.

Meanwhile, Vir Biotechnology has three clinical programs. The company thinks that its lead candidate, VIR-2218, which is being developed in collaboration with Alnylam Pharmaceuticals, holds the potential to be a functional cure for hepatitis B in combination with other therapies. Vir is also evaluating three COVID-19 therapies in pre-clinical testing.

Higher numbers of COVID-19 cases don't necessarily translate to greater prospects for any of these companies. But headlines about the pandemic definitely drive higher interest in their stocks.

The main thing to watch with each of these biotechs is their pipeline progress. For Dynavax, investors will also want to keep their eyes on sales of Heplisav-B in the coming quarters. Novavax expects to report initial results from its COVID-19 vaccine study in July. Vir plans to advance its VIR-7831 and VIR-7832 antibody therapies for COVID-19 directly into phase 2 testing this summer pending FDA review.

Go here to see the original:
Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today - The Motley Fool

Read More...

GAT-B 2020 and BET 2020 postponed, new dates to be announced soon – Careers360

June 27th, 2020 9:43 pm

NEW DELHI: Keeping in view the Covid-19 situation, Regional Centre for Biotechnology (RCB), Faridabad has postponed the Graduate Aptitude Test 2020 which was scheduled for June 30.

The Department of Biotechnology, Ministry of Science and Technology has also postponed the Biotechnology Eligibility Test 2020 which was also scheduled on June 30.

The new dates of the GAT-B 2020 and BET-2020 exam will be announced soon. The admit card of GAT-B 2020 was released on June 25. However, the admit card link has been removed now. The admit card of GAT-B 2020 will be released again.

The All India level entrance examination of GAT-B 2020 is conducted for admission to DBT- supported postgraduate programmes in all the participating institutions.

Biotechnology Eligibility Test is conducted to award the DBT-Junior Research Fellowship for pursuing research in biotechnology and life sciences.

Write to us at news@careers360.com

Stay updated with latest Education News

More From Team Careers360

Visit link:
GAT-B 2020 and BET 2020 postponed, new dates to be announced soon - Careers360

Read More...

Molecular Biology Enzymes and Kits & Reagents Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive…

June 27th, 2020 9:42 pm

Expanding number of life science and research-based associations worldwide has accounted high number of innovative work exercises, this has added to the developing interest for catalysts and reagents. Increasing utilization of these proteins and reagents in biotechnology and pharmaceutical organizations and scholarly foundations have brought about an expansion sought after for better than ever items, which will additionally add to this current markets development. Additionally, government activities in biotechnology industry will support the request from this market, subsequently this will add to the development sought after for atomic science catalysts, units and reagents. Some of the real driving variables for the development of this market incorporate expanding innovative work exercises in biotechnology research and medication disclosure, rising number of uses for these proteins and reagents and expanding interest for as good as ever chemicals and reagents.

The Molecular Biology Enzymes and Kits & Reagents Market is expected to exceed more than US$ 17.0 Billion by 2024 at a CAGR of 17% in given forecast period.

Browse Full Report: https://www.marketresearchengine.com/molecular-biology-enzymes-and-kits-and-reagents-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Inc. (U.S.), Merck KGaA (Germany), New England Bio labs, Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), Becton, Dickinson and Company (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), and Takara Bio, Inc. (Japan).Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The global molecular biology enzymes and kits & reagents market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional molecular biology enzymes and kits & reagents market and analyzes the variations in the growth of the industry in certain regions.

The scope of the report includes a detailed study of global and regional markets onMolecular Biology Enzymes and Kits & Reagents Marketwith the reasons given for variations in the growth of the industry in certain regions.

The restraining factors of Molecular Biology Enzymes and Kits & Reagents Market are as follows:

The major driving factors of Molecular Biology Enzymes and Kits & Reagents Market are as follows:

The Molecular Biology Enzymes and Kits & Reagents Market has been segmented as below: (Accordingly)

The Molecular Biology Enzymes and Kits & Reagents Market is Segmented on the lines of Application Analysis, Product Analysis, End User Analysis and Regional Analysis. By Application Analysis this market is segmented on the basis of PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology and Other Applications. By Product Analysis this market is segmented on the basis of Kits & Reagents and Enzymes its covers Polymerases, Ligases, Restriction Endo nucleases, Reverse Transcriptases, Phosphatases, Proteases and Proteinases & Other Enzymes.

By End User Analysis this market is segmented on the basis of Academic & Research Institutes sector, Hospitals & Diagnostic Centers sector, Pharmaceutical & Biotechnology companies sector and Other End Users sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Molecular Biology Enzymes and Kits & Reagents Market and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for Molecular Biology Enzymes and Kits & Reagents Market.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

Request Sample Report: https://www.marketresearchengine.com/molecular-biology-enzymes-and-kits-and-reagents-market

Table of Contents

1 INTRODUCTION

2 Molecular Biology Kits Market: Research Methodology

3 Molecular Biology Kits Market: Executive Summary

3.1 Introduction3.2 Current Scenario3.3 Future Outlook3.4 Conclusion

4 Premium Insights

5 Molecular Biology Kits Market: Market Overview

6 Industry Insights

7 Global Molecular Biology Enzymes and Kits & Reagents Market, By Product

8 Global Molecular Biology Enzymes and Kits & Reagents Market, By Application

9 Molecular Biology Enzymes and Kits & Reagents Market, By End User

10 Molecular Biology Enzymes and Kits & Reagents Market, By Region

11 Competitive Landscape

12 Company Profiles

12.1 Introduction

12.2 Thermo Fisher Scientific, Inc.

12.3 Merck KGAA

12.4 Promega Corporation

12.5 New England Bio labs, Inc.

12.6 Illumina, Inc.

12.7 Takara Bio Inc.

12.8 Qiagen N.V.

12.9 Agilent Technologies, Inc.

12.10 F. Hoffmann-La Roche Ltd

12.11 Becton, Dickinson and Company

Other Related Market Research Reports:

Microbiology Culture Market is Determined to Cross US$ 7 Billion By 2023

Human Genetics Market Latest Industry Scenario, Trends, Share & Future Forecast By 2016 to 2022

Depth Filtration Market is Projected to Reach US$ 3 Billion By 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Go here to see the original:
Molecular Biology Enzymes and Kits & Reagents Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive...

Read More...

Cell Sorter Market 2020 Report Forecasts the Impact of COVID-19 Pandemic on Business and future opportunity | Beckman Coulter, Bio-Rad Laboratories,…

June 27th, 2020 9:42 pm

Current Trend 2020: Latest Analysis on Cell Sorter Market

Toronto, Canada: The report involves insightful data on the main sectors of theGlobal Cell Sorter Market. The report has segmented market, by its types and applications. Each segment has analyzed completely on the basis of its production, consumption as well as revenue. Further, it is classified on the basis of geographical areas which include: North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

SDMR Research has recently published a report, titled COVID-19 Impact on Global Cell Sorter Market Insights, Forecast to 2025. The market research report is a brilliant, complete, and much-needed resource for Cell Sorter . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Cell Sorter market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Cell Sorter market are: Beckman CoulterBio-Rad LaboratoriesSony BiotechnologyMiltenyi BiotecAffymetrixSysmex PartecOn-Chip BiotechnologiesCytonomeBecton DickinsonUnion Biometrica

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)

The study is a source of reliable data on:

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

Segmental Analysis:

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Cell Sorter Market Segment By Type:

Cell SortersCell Sorting Reagents & ConsumablesCell Sorting Services

Global Cell Sorter Market Segment By Application:Research ApplicationClinical Applications

Competitive Landscape:

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key questions answered in the report:

What is the growth potential of the Cell Sorter market?

Which product segment will grab a lions share?

Which regional market will emerge as a frontrunner in the coming years?

Which application segment will grow at a robust rate?

What are the growth opportunities that may emerge in the Cell Sorter industry in the years to come?

What are the key challenges that the global Cell Sorter market may face in the future?

Which are the leading companies in the global Cell Sorter market?

Which are the key trends positively impacting the market growth?

Which are the growth strategies considered by the players to sustain hold in the global Cell Sorter market?

Grab Best Discount on Cell Sorter Market Research Report [Single User | Multi User | Corporate Users] @ https://www.supplydemandmarketresearch.com/home/contact/1288380?ref=Discount&toccode=SDMRLI1288380

TOC:

Report Overview: It includes major players of the global Cell Sorter market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Cell Sorter market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Cell Sorter market are discussed.

Market Share by Manufacturers/Keyplayers : Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Cell Sorter market by application, it gives a study on the consumption in the global Cell Sorter market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles: Almost all leading players of the global Cell Sorter market are profiled in this section. The analysts have provided information about their recent developments in the global Cell Sorter market, products, revenue, production, business, and company.

Market Forecast by Production: The production and production value forecasts included in this section are for the global Cell Sorter market as well as for key regional markets.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the global Cell Sorter market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the global Cell Sorter market.

Key Findings: This section gives a quick look at the important findings of the research study.

Contact Us: Nimesh H302-20 Misssisauga, Valley, Missisauga,L5A 3S1, Toronto, Canada Phone Number: +1-276-477-5910Email- [emailprotected]

For More Information Kindly Contact: We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

The rest is here:
Cell Sorter Market 2020 Report Forecasts the Impact of COVID-19 Pandemic on Business and future opportunity | Beckman Coulter, Bio-Rad Laboratories,...

Read More...

Preparative And Process Chromatography Market Overview on Future Threats the COVID-19 – Cole of Duty

June 27th, 2020 9:42 pm

Global Preparative and Process Chromatography Market was valued US$6.27 Billion in 2018 and is expected to reach US$9.70 Billion by 2026 at a CAGR of about 5.61% during a forecast year.

The global preparative and process chromatography report is segmented into four different categories such as product type, application, end-user, and region. Based on product type, the global preparative and process chromatography categorised into chromatography instruments, accessories, and others. Depending upon second category the global preparative and process chromatography market is further segmented into its application areas such as clinical diagnostics, environmental testing, food & beverage analysis, forensic tests, life sciences, and others. The third category of global preparative and process chromatography is end users such as agriculture and food industries, hospital and research laboratories, biotechnology and pharmaceutical industries, and others. Based on region, global preparative and process chromatography market is classified into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/10692

The global preparative and process chromatography market is highly driven by increasing demand for insulin and other biopharmaceutical products purification, technological advancements. Emerging countries such as India, China, and Brazil providing opportunities for the players, which are in the preparative and process chromatography market. Though, the huge expense of instrument and substitute techniques for purification and separation of pharmaceutical products are the main restraining issues for this market.

The global preparative and process chromatography market is divided into product such as chromatography instruments, accessories, and others. The process chromatography leads the market due increasing in production of monoclonal antibodies and insulin in biotechnology and pharmaceutical industries.In application, global preparative and process chromatography is divided in clinical diagnostics, environmental testing, food & beverage analysis, forensic tests, life sciences, and others. Among these, clinical and food & beverages is the fastest growing market due increasing the global human population.

Based on end-users, such as agriculture and food industries, hospital and research laboratories, biotechnology and pharmaceutical industries, and others. Biotechnology and pharmaceutical industries account for the principal share of the global market in 2018, due to increasing research activities by pharmaceutical and biotechnological companies and increasing research and development programme for production of monoclonal antibodies and insulin.

Asia Pacific is expected to register the highest growth rate during the forecast year. The growth in this market is mainly driven by the growing demand for preparative and process chromatography techniques in life sciences, biotechnology, and food & beverage areas and the geographic expansion of key chromatography players in this market.

Some of the key players in global preparative and process chromatography market are: GE Healthcare, Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Agilent Technologies, Novasep Holding S.A.S, Waters Corporation, Daicel Corporation, and Shimadzu Corporation.Scope of Global Preparative and Process Chromatography Market:Global Preparative and Process Chromatography Market, By Product:Process Chromatographyo Solid Supports and Reagentso Resinso Columnso Systemo ServicesPreparative Chromatographyo Solid Supports and Reagentso Resinso Columnso Systemso ServicesGlobal Preparative and Process Chromatography Market, By End user:Agriculture and food industriesHospital and research laboratoriesBiotechnology and pharmaceutical industriesOthersGlobal Preparative and Process Chromatography Market, By Application:Clinical diagnosticsEnvironmental testingFood & beverage analysisForensic testsLife sciencesOthersGlobal Preparative and Process Chromatography Market, By Region:North AmericaEuropeAsia PacificMiddle East & AfricaSouth AmericaKey Players Operating In Global Preparative and Process Chromatography Market:GE HealthcareMerck KGaADanaher CorporationBio-Rad LaboratoriesThermo Fisher ScientificAgilent TechnologiesNovasep Holding S.A.SWaters CorporationDaicel CorporationShimadzu CorporationPall CorporationChiral Technologies, Inc.AgilentAPIXBrukerBuck ScientificCDS AnalyticalFalcon AnalyticalGenTechParker BalstonQuadrexSRI InstrumentsTeledyne TekmarTorionZoex

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/10692

Read the original post:
Preparative And Process Chromatography Market Overview on Future Threats the COVID-19 - Cole of Duty

Read More...

Hemp Genetics CEO on Selecting the Right Strains – Greenhouse Grower

June 26th, 2020 4:53 pm

The sheer volume of genetics in the hemp and legal cannabis markets introduces a bit of uncertainty into perhaps the most important decision a commercial cannabis grower will make all year. Its definitely not as easy a choice as Coke vs. Pepsi(#TeamCoke!)

Whether youre growing hemp for pure biomass yield, greenhouse cannabis flower for the top shelf down at the local dispensary, or producing exclusively for the extraction market, making the right decision with your seed or clone salesperson can often make or break a farmers crop.

As part of last weeks Experience Hemp: Summer Solstice Virtual Conference and Trade Show, Beacon Hemp CEO Nick Stromberg gave a brief presentation laying out the factors hemp growers should keep in mind when selecting their genetic material at the start of the grow season.

I cant stress enough how very important it is to keep the end use of the plant in mind at all times when selecting the best hemp genetics for your farm and for the product youre creating, Stromberg explained to the virtual audience. Am I growing for oil extraction, or fiber and biomass? Will I field dry it, or mechanical dry it? Am I trying for high end CBD or CBG production? Those are just a few of the sort of things you need to have in mind.

How your plants get their start in life is another factor to weigh heavily when selecting strains, according to Stromberg.

Thats another consideration: How are you propagating your starts? And if you dont have a lot of hands on experience in this area, then we highly recommend working with a professional propagator, he said. Uniform, well-hardened seedlings are very key to securing success in this market.

Hemp and cannabis growers have bemoaned a general lack of professionalism among breeders in the segment for years now, with the criticism only growing louder as more states legalize cannabis and hemp production and more growers get burned by bad actors in the seed game. It happens more often that youd think, and Stromberg had some thoughts on how to best evaluate a potential genetics partner.

The Certificate of Analysis (CoA) is going to be one of the biggest selling points that any seed salesman or broker will use to try to sell you, he said. On that document, you want to look closely at both the CBD to THC ratio, or the proportion of CBD to THC in that strain this should be more or less in the mid 20:1 into the low 30:1, and then whether the data youre looking at is from a pre-harvest or a post-harvest CoA.

Those THC/CBD levels should remain fixed throughout the crops development, regardless of growing stage, Stromberg advised. The pre-harvest CoA is your official CoA, and the post-harvest CoA will often go over the .03% THC cap and typically be in the mid to high teens on CBD content, depending how long the pre-harvest interval lasted.

The seed packaging itself should have a certain level of disclosed information about the strain or cultivar contained within as well, Stromberg advised. While Association of Seed Certifying Agency (AOSCA) certified hemp varieties are currently few and far between (AOSCA certification wont come to legal cannabis genetics until federal legalization is passed) with the certification process still in its early stages, a seed tag, or label, should conceivably track somewhat closely (generally speaking) to what corn and soy farmers see when they pick up a bag of RoundupReady2Xtend corn. (SPOILER ALERT: Right now, they dont. A standardization of the reporting process on cannabis and hemp seed labels would be a great thing for growers in this industry, but thats perhaps a subject for another day)

Federal Seed Act compliant labels will list things like germination rate and purity test results those two specifically are legally required to be listed on the seed label as well things like seed lot numbers, dates of testing, all those types of things, he said.Stromberg perhaps saved his best advice for growers for last.

Ask for any additional information on the genetics and its pedigree ask about their background as a plant breeder, the length of the breeding project, their production methods was it produced in the field, or in a greenhouse? And when was it produced ask these questions and youll probably be able to find the legitimate ones are willing to reveal this type of information where others maybe wont.

And ask for regionally significant trial data, he added. If you grow in North Carolina and all the field data is from Oregon, thats probably not what you want to see. The good news is theres been a lot more field trials planted this year. So, going into 2021, there should be a lot more field trial data for those breeders and seed salesmen to hang their hats on.

Want to learn more about commercial hemp varieties? Stay tuned in August for our first-ever commercial hemp varieties guide (alongside our annual coverage of ornamental and greenhouse vegetable varieties).

Matthew J. Grassi is the Technology Editor for Greenhouse Grower and American Vegetable Grower, both Meister Media Worldwide brands. See all author stories here.

See the original post:
Hemp Genetics CEO on Selecting the Right Strains - Greenhouse Grower

Read More...

Race Is Real, But It’s Not Genetic – Discover Magazine

June 26th, 2020 4:53 pm

A friend of mine with Central American, Southern European, and West African ancestry islactose intolerant. Drinking milk products upsets her stomach, and so she avoids them. About a decade ago, because of her low dairy intake, she feared that she might not be getting enough calcium, so she asked her doctor for abone density test. He responded that she didnt need one because blacks do not get osteoporosis.

My friend is not alone. The view that black people dont need a bone density test is a longstanding and common myth. A2006 studyin North Carolina found that out of 531 African American and Euro-American women screened for bone mineral density, only 15 percent were African American womendespite the fact that African American women made up almost half of that clinical population. A health fair in Albany, New York, in 2000,turned into a ruckuswhen black women were refused free osteoporosis screening. The situationhasnt changed muchin more recent years.

Meanwhile,FRAX, a widely used calculatorthat estimates ones risk of osteoporotic fractures, is based on bone density combined with age, sex, and, yes, race. Race, even though it is never defined or demarcated, is baked into the fracture risk algorithms.

Lets break down the problem.

First, presumably based on appearances, doctors placed my friend and others into a socially defined race box called black, which is a tenuous way to classify anyone.

Race is a highly flexible way in which societies lump people into groups based on appearance that is assumed to be indicative of deeper biological or cultural connections. As a cultural category, the definitions and descriptions of races vary. Color lines based on skin tone can shift, which makes sense, but the categories are problematic for making any sort of scientific pronouncements.

Second, these medical professionals assumed that there was a firm genetic basis behind this racial classification, which there isnt.

Third, they assumed that this purported racially defined genetic difference would protect these women from osteoporosis and fractures.

Some studies suggestthat African American womenmeaning women whose ancestry ties back to Africamay indeed reach greater bone density than other women, which could be protective against osteoporosis. But that does not mean being blackthat is, possessing an outward appearance that is socially defined as blackprevents someone from getting osteoporosis or bone fractures. Indeed, this same research also reports that African American women are more likely to die after a hip fracture. The link between osteoporosis risk and certain racial populations may be due to lived differencessuch as nutritionandactivity levels, both of which affect bone density.

But more important:Geographicancestry is not the same thing as race. African ancestry, for instance, does not tidily map onto being black (or vice versa). In fact, a2016 studyfound wide variation in osteoporosis risk among women living in different regions within Africa. Their genetic risks have nothing to do with their socially defined race.

When medical professionals or researchers look for ageneticcorrelateto race, they are falling into a trap: They assume thatgeographic ancestry, which does indeed matter to genetics, can be conflated with race, which does not. Sure, different human populations living in distinct places may statistically have different genetic traitssuch as sickle cell trait (discussed below)but such variation is aboutlocal populations(people in a specific region), not race.

Like a fish in water, weve all been engulfed by the smog of thinking that race is biologically real. Thus, it is easy to incorrectly conclude that racial differences in health, wealth, and all manner of other outcomes are the inescapable result of genetic differences.

The reality is that socially defined racial groups in the U.S. and most everywhere else do differ in outcomes. But thats not due to genes. Rather, it is due to systemic differences in lived experience and institutional racism.

Communities of color in the United States, for example, often have reduced access to medical care, well-balanced diets, andhealthy environments. They are often treated more harshly in their interactions withlaw enforcement and the legal system. Studies show that they experience greater social stress, includingendemic racism, that adversely affects all aspects of health. For example, babies born to African American women are more thantwice as likely to diein their first year than babies born to non-Hispanic Euro-American women.

Systemic racism leads to different health outcomes for various populations. The infant mortality rate, for example, for African American infants is double that for European Americans. (Credit: Kelly Lacy/Pexels)

As a professor of biological anthropology, I teach and advise college undergraduates. While my students are aware of inequalities in the life experiences of different socially delineated racial groups, most of them also think that biological races are real things. Indeed, more than half of Americans still believe that their racial identity is determined byinformation contained in their DNA.

For the longest time, Europeans thought that the sun revolved around the Earth. Their culturally attuned eyes saw this as obvious and unquestionably true. Just as astronomers now know thats not true,nearly all population geneticistsknow that dividing people into races neither explains nor describes human genetic variation.

Yet this idea of race-as-genetics will not die. For decades, it has been exposed to the sunlight of facts, but, like a vampire, it continues to suck bloodnot only surviving but causing harm in how it can twist science to support racist ideologies. With apologies for the grisly metaphor, it is time to put a wooden stake through the heart of race-as-genetics. Doing so will make for better science and a fairer society.

In 1619, the first people from Africa arrived in Virginia and became integrated into society. Only after African and European bond laborers unified in various rebellions did colony leaders recognize the need to separate laborers.Race dividedindentured Irish and other Europeans from enslaved Africans, and reduced opposition by those of European descent to the intolerable conditions of enslavement. What made race different from other prejudices, including ethnocentrism (the idea that a given culture is superior), is that it claimed that differences were natural, unchanging, and God-given. Eventually, race also received the stamp of science.

Over the next decades, Euro-American natural scientists debated the details of race, asking questions such as how often the races were created (once, as stated in the Bible, or many separate times), the number of races, and their defining, essential characteristics. But they did not question whether races were natural things. They reified race, making the idea of race real by unquestioning, constant use.

In the 1700s, Carl Linnaeus, the father of modern taxonomy and someone not without ego, liked to imagine himself asorganizing what God created. Linnaeus famously classified ourown species into racesbased on reports from explorers and conquerors.

The race categories he created includedAmericanus,Africanus, and evenMonstrosus(for wild and feral individuals and those with birth defects), and their essential defining traits included a biocultural mlange of color, personality, and modes of governance. Linnaeus describedEuropeausas white, sanguine, and governed by law, andAsiaticusas yellow, melancholic, and ruled by opinion. These descriptions highlight just how much ideas of race are formulated by social ideas of the time.

Swedish taxonomist Carl Linnaeus divided humanity up into racial categories according to his notion of shared essences among populations, a concept researchers now recognize has no scientific basis. (Credit: Wikimedia Commons/Public Domain)

In line with early Christian notions, these racial types were arranged in a hierarchy:a great chain of being, from lower forms to higher forms that are closer to God. Europeans occupied the highest rungs, and other races were below, just above apes and monkeys.

So, the first big problems with the idea of race are that members of a racial group do not share essences, Linnaeus idea of some underlying spirit that unified groups, nor are races hierarchically arranged. A related fundamental flaw is that races were seen to be static and unchanging. There is no allowance for a process of change or what we now call evolution.

There have been lots of efforts since Charles Darwins time to fashion the typological and static concept of race into an evolutionary concept. For example, Carleton Coon, a former president of the American Association of Physical Anthropologists, argued inThe Origin of Races(1962) that five racesevolved separatelyand became modern humans at different times.

One nontrivial problem with Coons theory, and all attempts to make race into an evolutionary unit, is that there is no evidence. Rather, all the archaeological and genetic data point to abundant flows of individuals, ideas, and genes across continents, withmodern humansevolving at the same time, together.

Afew pundits such asCharles Murrayof the American Enterprise Institute and science writers such asNicholas Wade, formerly ofThe New York Times, still argue that even though humans dont come in fixed, color-coded races, dividing us into races still does a decent job ofdescribinghuman genetic variation. Their position is shockingly wrong. Weve known for almost 50 years that race does not describe human genetic variation.

In 1972, Harvard evolutionary biologist Richard Lewontinhad the idea to testhow much human genetic variation could be attributed to racial groupings. He famously assembled genetic data from around the globe and calculated how much variation was statistically apportioned within versus among races. Lewontin found that only about 6 percent of genetic variation in humans could be statistically attributed to race categorizations. Lewontin showed that the social category of race explains very little of the genetic diversity among us.

Furthermore, recent studies reveal that the variation between any two individuals isverysmall, on the order of onesingle nucleotide polymorphism(SNP), or single letter change in our DNA, per 1,000. That means that racial categorization could, at most, relate to 6 percent of the variation found in 1 in 1,000 SNPs. Put simply, race fails to explain much.

In addition, genetic variation can be greaterwithingroups that societies lump together as one race than it is between races. To understand how that can be true, first imagine six individuals: two each from the continents of Africa, Asia, and Europe. Again, all of these individuals will be remarkably the same: On average, only about 1 out of 1,000 of their DNA letters will be different. A study by Ning Yu and colleaguesplaces the overall differencemore precisely at 0.88 per 1,000.

The researchers further found that people in Africa had less in common with one another than they did with people in Asia or Europe. Lets repeat that: On average, two individuals in Africa aremoregenetically dissimilar from each other than either one of them is from an individual in Europe or Asia.

Homo sapiensevolved in Africa; the groups that migrated out likely did not include all of the genetic variation that built up in Africa. Thats an example of what evolutionary biologists call thefounder effect, where migrant populations who settle in a new region have less variation than the population where they came from.

Genetic variation across Europe and Asia, and the Americas and Australia, is essentially a subset of the genetic variation in Africa. If genetic variation were a set of Russian nesting dolls, all of the other continental dolls pretty much fit into the African doll.

What all these data show is that the variation that scientistsfrom Linnaeus to Coon to the contemporary osteoporosis researcherthink is race is actually much better explained by a populationslocation. Genetic variation is highly correlated togeographic distance. Ultimately, the farther apart groups of people are from one another geographically, and, secondly, the longer they have been apart, can together explain groups genetic distinctions from one another. Compared to race, those factors not only better describe human variation, they invoke evolutionary processes to explain variation.

Those osteoporosis doctors might argue that even though socially defined race poorly describes human variation, it still could be a useful classification tool in medicine and other endeavors. When the rubber of actual practice hits the road, is race a useful way to make approximations about human variation?

When Ive lectured at medical schools, my most commonly asked question concerns sickle cell trait. Writer Sherman Alexie, a member of the Spokane-Coeur dAlene tribes, put the question this wayin a 1998 interview: If race is not real, explain sickle cell anemia to me.

OK! Sickle cell is a genetic trait: It is the result of an SNP that changes the amino acid sequence of hemoglobin, the protein that carries oxygen in red blood cells. When someone carries two copies of the sickle cell variant, they will have the disease. In the United States, sickle cell disease is most prevalent in people who identify as African American, creating the impression that it is a black disease.

(Credit: SciePro/Shutterstock)

Yet scientists have known about the much more complexgeographic distributionof sickle cell mutation since the 1950s. It is almost nonexistent in the Americas, most parts of Europe and Asiaand also in large swaths of Northern and Southern Africa. On the other hand, it is common in West-Central Africa and also parts of the Mediterranean, Arabian Peninsula, and India. Globally, it does not correlate with continents or socially defined races.

Inone of the most widely citedpapers in anthropology, American biological anthropologist Frank Livingstone helped to explain the evolution of sickle cell. He showed that places with a long history of agriculture and endemic malaria have a high prevalence of sickle cell trait (a single copy of the allele). He put this information together with experimental and clinical studies that showed how sickle cell trait helped people resist malaria, and made a compelling case for sickle cell trait being selected for in those areas.Evolution and geography, not race, explain sickle cell anemia.

What about forensic scientists: Are they good at identifying race? In the U.S., forensic anthropologists are typically employed by law enforcement agencies to help identify skeletons, including inferences about sex, age, height, and race. The methodological gold standards for estimating race are algorithms based on a series of skull measurements, such as widest breadth and facial height. Forensic anthropologists assume thesealgorithms work.

The origin of the claim that forensic scientists are good at ascertaining race comes from a 1962 study of black, white, and Native American skulls, which claimed an 8090 percent success rate. That forensic scientists are good at telling race from a skull is a standard trope of both thescientific literatureandpopular portrayals.But my analysisof four later tests showed that the correct classification of Native American skulls from other contexts and locations averaged about two incorrect for every correct identification. The results are no better than a random assignment of race.

Thats because humans are not divisible into biological races. On top of that, human variation does not stand still. Race groups are impossible to define in any stable or universal way. It cannot be done based on biologynot by skin color, bone measurements, or genetics. It cannot be done culturally: Race groupings have changed over time and place throughout history.

Science 101: If you cannot define groups consistently, then you cannot make scientific generalizations about them.

Skull measurements are a longstanding tool in forensic anthropology. (Credit: Internet Archive Book Images/Flickr/Public Domain)

Wherever one looks, race-as-genetics is bad science. Moreover, when society continues to chase genetic explanations, it misses the larger societal causes underlying racial inequalities in health, wealth, and opportunity.

To be clear, what I am saying is that human biogenetic variation is real. Lets just continue to study human genetic variation free of the utterly constraining idea of race. When researchers want to discuss genetic ancestry or biological risks experienced by people in certain locations, they can do so without conflating these human groupings withracial categories. Lets be clear that genetic variation is an amazingly complex result of evolution and mustnt ever be reduced to race.

Similarly, race is real, it just isnt genetic. Its a culturally created phenomenon. We ought to know much more about the process of assigning individuals to a race group, including the category white. And we especially need to know more about the effects of living in a racialized world: for example, how a societys categoriesand prejudiceslead to health inequalities. Lets be clear that race is a purely sociopolitical construction with powerful consequences.

It is hard to convince people of the dangers of thinking race is based on genetic differences. Like climate change, the structure of human genetic variation isnt something we can see and touch, so it is hard to comprehend. And our culturally trained eyes play a trick on us by seeming to see race as obviously real. Race-as-genetics is even more deeply ideologically embedded than humanitys reliance on fossil fuels and consumerism. For these reasons, racial ideas will prove hard to shift, but it is possible.

Over 13,000 scientistshave come together to formand publicizea consensus statement about the climate crisis, and that has surely moved public opinion to align with science. Geneticists and anthropologists need to do the same for race-as-genetics. The recent American Association of Physical AnthropologistsStatement on Race & Racismis a fantastic start.

In the U.S., slavery ended over 150 years ago and the Civil Rights Law of 1964 passed half a century ago, but the ideology of race-as-genetics remains. It is time to throw race-as-genetics on the scrapheap of ideas that are no longer useful.

We can start by getting my friendand anyone else who has been deniedthat long-overdue bone density test.

Alan Goodmanis a professor of biological anthropology at Hampshire College in Massachusetts. This story was originally posted onSAPIENS. Read the original articlehere.

Follow this link:
Race Is Real, But It's Not Genetic - Discover Magazine

Read More...

Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology – PRNewswire

June 26th, 2020 4:53 pm

The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and services available. Integrating germline testing, tumor profiling and liquid biopsy technologies and services in a single platform will enable precision approaches from diagnostic testing to therapy optimization and monitoring, expanding access to best-in-class personalized oncology.

"From the beginning, Invitae's goal has been to aggregate the world's genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine. Today, we take another major step forward in that effort," said Sean George, Ph.D., co-founder and chief executive officer of Invitae.

"ArcherDXand Invitae share a foundational belief in the power of genomic information toimpact care. We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value," said Jason Myers, Ph.D., chief executive officer and co-founder of ArcherDX. "ArcherDXwas founded to democratize precision oncology with best-in-class products that are personal, actionable and available in local care settings. We see STRATAFIDE DX as a significant near-term value driver, currently under development for cancer therapy optimization, while PCM provides an exciting opportunity to transform cancer care through multiple monitoring applications. ArcherDXproducts, workflow and powerful bioinformatics solutions provide an opportunity to advance precision oncology into regional and community settings and address an estimated $45 billion market opportunity. Together with Invitae, we look forward to expanding our impact beyond oncology, driving significant value through shared expertise to inform healthcare throughout life, globally."

"Integrating all aspects of cancer genetics can transform care for patients and the flexibility that comes from both centralized and decentralized capabilities will uniquely position Invitae to meet the needs of customers worldwide," continued Dr. George. "By joining together, we will unite world-class capabilities in the hands of a talented team with complementary expertise and strong brands in service of a shared goal to improve healthcare for patients."

Accelerating access and adoption of genetics to improve cancer care

Broad adoption of precision oncology has been limited, particularly in regional and community settings where approximately 85 percent of patients receive care.1 Without precision oncology, late-stage cancer patients can suffer from poor prognosis and outcomes, while early-stage patients may receive an inaccurate prognosis that results in unnecessary treatment and delayed detection of recurrence.2,3

Uniting Invitae and ArcherDXwill offer comprehensive support for precision oncology.

With both centralized and local testing capabilities, the combined organization will offer breadth and flexibility in serving customers in more than 95 markets. Together, Invitae and ArcherDXwill offer robust support for biopharmaceutical companies, from patient identification and screening, to biomarker identification and companion diagnostic development.

Transaction Terms

Under the terms of the agreement, Invitae will acquire ArcherDXfor upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX.

Financing Activities

In connection with the proposed combination, Invitae has arranged a strategic financing with over $400 million in financing commitments from a premier syndicate of life sciences investors, led by Perceptive Advisors. Invitae has entered into a definitive agreement to sell $275 million in common stock in a private placement at a price of $16.85 per share. The private placement is being supported by key existing investors in Invitae and Archer, including Casdin Capital, Deerfield Management, Driehaus Capital Management, Farallon, PBM Capital, Perceptive Advisors, Redmile Group, Rock Springs Capital, Soleus Capital, and one additional institutional investor. The placement is expected to close concurrently with the proposed combination, subject to the satisfaction of customary closing conditions. Invitae has also entered into a fully committed credit facility for up to $200 million with Perceptive Credit Opportunities Funds, subject to certain customary closing conditions.

Since the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, Invitae has sold under its ATM facility approximately 2.6 million shares of common stock for aggregate gross proceeds of $46 million at an average price of $17.59 per share.

Invitae's current expectations regarding its cash at transaction close would be approximately $425 million and its annualized near-term forward cash burn is expected to be approximately $130 million.

Advisors

Perella Weinberg Partners served as lead financial advisor to Invitae in connection with the business combination and Cowen served as co-financial advisor. Cowen served as lead-placement agent to Invitae for the private placement and Perella Weinberg Partners served as co-placement agent; Cowen served as exclusive financial advisor to Invitae in connection with the senior secured term loan facility. Evercore and J.P. Morgan Securities LLC acted as financial advisors to Archer.

Webcast

Management will host a conference call and webcast today at 5:00 a.m. PT / 6:00 a.m. MT / 8:00 a.m. ET to discuss the transaction. The dial-in numbers for the conference call are (866) 324-3683 for domestic callers and (509) 844-0959 for international callers, and the reservation number for both is 7097864. Please note, after dialing in, you will be prompted to enter the Conference ID and then the pound "#" sign to enter the call. Following prepared remarks, management will respond to questions from analysts, subject to time limitations.

The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website atir.invitae.com.A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

About Invitae

Invitae Corporation(NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website atinvitae.com.

About ArcherDX

ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. Our ArcherDXplatform, with our proprietary Anchored Multiplex PCR (AMP) chemistry at the core, has enabled us to develop industry-leading products and services with the goal to optimize therapy and enable cancer monitoring across sample types. We develop and commercialize research products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. Our research product portfolio consists of VariantPlex, FusionPlex, LiquidPlex and Immunoverse, which we collectively refer to as ArcherPlex. IVD products currently in development for solid tumor biomarker identification and Personalized Cancer Monitoring (PCM) have both received Breakthrough Device Designation from the FDA. ArcherDXis headquartered in Boulder, Colorado. Learn more at http://www.archerdx.comand follow @ArcherDXIncon Twitter, Facebookand LinkedIn.

Safe Harbor Statement

This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae") that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans, objectives, and the proposed acquisition of Archer by Invitae are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding expected future operating results, including cash at closing and annualized forward cash burn, drivers of future value, future products and services and customers served, regulatory submissions, anticipated results of product development efforts, potential addressable markets, the impact of Covid-19, the anticipated benefits of the proposed acquisition of Archer, including expected synergies, opportunities, product offerings, and financial and other impacts, the transaction structure and financing plans, and the expected timing of completion of the proposed transaction. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of Covid-19 on the business of Invitae and Archer; Invitae's ability to manage its growth effectively; the ability of Invitae and Archer to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; the ability of Invitae and Archer to obtain and maintain regulatory approvals and comply with applicable regulations; the ability of Invitae and Archer to obtain the required regulatory approvals for the proposed merger and the approval of Invitae's and Archer's stockholders, and to satisfy the other conditions to the closing of the acquisition and related financing transactions on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of Invitae and Archer to terminate the merger agreement; negative effects of the announcement or the consummation of the acquisition on the market price of Invitae's common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the proposed acquisition of Archer cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the proposed acquisition of Archer; risks associated with transaction-related litigation; the possibility that costs or difficulties related to the integration of Archer's operations with those of Invitae will be greater than expected; the ability of companies individually and the combined company to retain and hire key personnel; Invitae's failure to manage growth effectively; Invitae's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; Invitae's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to Invitae's business, and the risks and uncertainties set forth in Invitae's reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by Invitae from time to time. There can be no assurance that the proposed acquisition of Archer will in fact be consummated in the manner described or at all. Forward -looking statements speak only as of the date hereof, and Invitae disclaims any obligation to update any forward-looking statements.

NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners.

Additional Information and Where to Find It

In connection with the proposed transaction, Invitae will file with the SEC a registration statement on Form S-4, which will include a document that serves as a proxy statement/prospectus of Invitae (the "proxy statement/prospectus"), and will file other documents regarding the proposed transaction with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. A definitive proxy statement/prospectus will be sent to Invitae's stockholders when it becomes available. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus free of charge from the SEC's website or from Invitae when it becomes available. The documents filed by Invitae with the SEC may be obtained free of charge at Invitae's website at http://www.invitae.com or at the SEC's website at http://www.sec.gov. These documents may also be obtained free of charge from Invitae by requesting them by mail at Invitae Corporation, 1400 16th Street, San Francisco, California 94103, or by telephone at (415) 374-7782.

Participants in the Solicitation

Invitae and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Invitae's directors and executive officers is available in Invitae's proxy statement dated April 29, 2020 for its 2020 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Stockholders, potential investors and other readers should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Invitae as indicated above.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Non-GAAP Financial Measures

Cash burn is a non-GAAP measure, is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. A limitation of using cash burn is that it does not represent the total change in cash, cash equivalents, and restricted cash for a period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about Invitae's historical operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn with such financial statements.

Cash burn is calculated as net increase or decrease in cash and cash equivalents and restricted cash less (a) changes in marketable securities, (b) cash received from equity and debt financings, (c) cash received from exercises of warrants, (d) cash payments made for business acquisitions, and (e) changes in unrealized gains and losses on marketable securities. A reconciliation to GAAP has not been provided as the reconciliation could not reasonably be estimated.

Contact for Invitae:Laura D'Angelo[emailprotected](628) 213-3369

Contact for ArcherDX:Andrea N. Flynn, Ph.D.Investor Relations & Corporate Communications[emailprotected]

1El-Deiry, W., et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. Cancer J Clin. 2019;69(4): 305-3432Hyman DM, et al. Implementing Genome-Driven Oncology. Cell. 2017;168(4):5845993Benayed, R, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. April 2019.

SOURCE Invitae Corporation

http://www.invitae.com

Read the original here:
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology - PRNewswire

Read More...

Blood type and genetics may determine your odds of contracting the coronavirus, study finds – MarketWatch

June 26th, 2020 4:53 pm

Factors such as age and underlying health conditions such as diabetes can put you at a higher risk of contracting coronavirus, according to the U.S. Centers for Disease Control and Prevention. But one more factor that could affect your chances of getting coronavirus is your blood type, at least according to one recent study.

People who have blood Type A were associated with a 45% higher risk of acquiring COVID-19 compared to people with other blood types, according to a study published Wednesday in the peer-reviewed New England Journal of Medicine by a team of European scientists. Meanwhile, people with blood Type O, the most common blood type, less likely to get coronavirus as people with other blood types.

Dont miss: Here are 9 hand sanitizers that the FDA warns can be toxic if absorbed by the body

The researchers arrived at this result after performing genetic analysis on more than 1,900 severely ill coronavirus patients in Spain and Italy and comparing them with over 2,000 patients who were not sick.

Also see: Heres a look at who is most at risk of contracting COVID-19 and how much they earn for taking that risk

A commonality they found was a DNA cluster which determines blood types, among other components within the human body. This prompted further research into which specific blood types were present in the majority of the severe cases of coronavirus they looked at.

Because the DNA cluster is found in other parts of the body, it may not be the case that blood type can predict ones risk of contracting coronavirus, said Roy Silverstein, a hematologist who is the chairman of the department of medicine at the Medical College of Wisconsin.

Those who are not Type A should not interpret this study to mean that they can let their guard down. Similarly, the data are not yet convincing enough to recommend that those with Type A need to do even more than what is recommended.

Those who are not type A should not interpret this study to mean that they can let their guard down, Silverstein, former president the American Society of Hematology, said. Similarly, the data are not yet convincing enough to recommend that those with Type A need to do even more than what is recommended.

Everyone needs to pay attention to COVID-19 prevention by following well-accepted guidelines related to social distancing, face covering, hand-washing, and self-isolation and testing in the setting of possible COVID-related symptoms.

A prior study published by the Southern University of Science and Technology in China, which has not been peer-reviewed, and a study by 23andMe, a privately held genetic-analysis company, pointed to similar results.

But even still, Silverstein urged people to take these findings with a grain of salt.

This study, along with other studies from China and from 23andMe all suggest, but do not prove, a statistical association between non-O blood type with either risk of infection with the COVID-19 virus, or with risk of developing severe disease if infected.

But the studies, he said, should prompt more rigorous clinical studies as well as basic science studies to probe the mechanisms by which ABO blood type and or ABO genes might influence coronavirus ability to infect cells or the bodys immune response to the virus.

More:
Blood type and genetics may determine your odds of contracting the coronavirus, study finds - MarketWatch

Read More...

Researchers say genetics may determine wound infection and healing – KLBK | KAMC | EverythingLubbock.com

June 26th, 2020 4:53 pm

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

Think of the last time you had a cut on your leg or foot. How long did it take for that wound to show signs of healing? If it was longer than three weeks, doctors would refer to it as a chronic wound. These types of non-healing wounds affect millions of people and are often associated with other chronic diseases or conditions like diabetes, decreased circulation and neuropathy.

But now, in a first-of-its-kind study, researchers have determined that genetics may play a role in how wounds heal.Caleb Phillips, an assistant professor at Texas Tech University and director of thePhillips Laboratoryin theDepartment of Biological Sciences, anddoctoral studentCraig Tipton led the study, Patient genetics is linked to chronic wound microbiome composition and healing, published Thursday (June 18) in the open-access, peer-reviewed medical journalPLOS Pathogens.

Phillips, who also serves as the Curator of Genetic Resources at theNatural Science Research Laboratorys (NSRL)Robert J. Baker Genetic Resources Collection, said the study determined that certain genes are associated with the number of bacteria and abundance of common pathogens in wounds. The collection of microbes, known as a microbiome, can determine how a wound heals and how long that process takes. The research also showed that the more diversity within a wound microbiome, the less time it took to heal.

A chronic wound is a serious burden, Phillips said. The median healing time of patients in this study was more than 200 days, but some people deal with these wounds for years. We were able to show that a persons genetics explain differences in the species that infect their wounds. The information in this study could be valuable in a clinical setting as pre-operative information to help inform preventative measures before a procedure, as some chronic wounds arise as non-healing surgical wounds, and could help inform a course of treatment for an existing infection.

Researchers included colleagues from Texas Tech, theTexas Tech University Health Sciences Center(TTUHSC), LubbocksSouthwest Regional Wound Care Center(SWRWCC) and the University of North Texas Health Science Center at Fort Worth (UNTHSC). Phillips said the project began after a conversation with Dr. Randy Wolcott, founder of the SWRWCC, where they discussed how certain patients develop multiple non-healing wounds over a long period. The microbiome within each wound was essentially the same. The researchers wanted to find out if this could be partially explained by genetics.

This study is big, Wolcott said. Its the initial study to find genes and/or gene alterations that correlate with what bacterial species can be more successful in causing infections in a specific patient. If a screen of a patients DNA prior to a surgery showed that patient is highly susceptible to a staphylococcus species, the doctor could mitigate staphylococcus complications.

Patients visiting the SWRWCC for the care of a lower-extremity infected wound consented to participation in the study and provided samples from their wound(s) and from a cheek swab. Samples like those collected at the SWRWCC are archived in liquid nitrogen at the Wolcott Wound Care Research Collection, a collection of the NSRLs Genetic Resources Collection that is specifically dedicated to wound care biology. The design of the study included an exploratory cohort of 79 patients, from which candidate locations of their genome were identified. This was followed by an experimental cohort of 85 patients, used to confirm associations between the genomic locations and wound microbiome characteristics.

The bacterial communities infecting an individuals wounds were determined by microbiome sequencing methods, and each patients genome was characterized at a few hundred thousand specific locations, called single nucleotide polymorphisms, or SNPs. A statistical approach was then used to determine which of these genomic locations explained differences in an individuals wound microbiome composition and was followed with several downstream analyses to understand the results.

We showed that there are identifiable locations in peoples genome where, depending on their genotype, they tend to get infections by specific bacteria, Phillips said. The different genomic locations identified tend to be related in terms of the types of genes they are close to and may regulate. A working hypothesis emerging from the research is that genetic differences influencing genes encoding the way our cells interact with the environment and each other are important for infection differences.

Tipton, who completed his bachelors degree in biology atAngelo State Universitybefore arriving at Texas Tech, said the project has been a significant part of his dissertation, which focuses on learning more about why a persons wounds are infected by different types of microbes. Though there is still work to be done before the research directly benefits patients, Tipton said the study is an important and promising step in that direction.

Personalized medicine is a current hot topic in modern healthcare, where the goal is to identify inherent differences within individuals that may cause them to be impacted differently by disease and finding treatments that are well-suited and tailored to the individual and may contribute to better patient outcomes, Tipton said. Our project furthers two equally-interesting avenues of research with potential translation to the clinic. In one, it is our goal to develop robust genomic predictive models that could help physicians to determine a patients risk for chronic wound infection, particularly to specific bacteria.

In the second, this work helps to inform how genetic variation in patients can influence microbiome-host interactions and wound infection pathogenesis. By further studying infection pathogenesis and how these complex microbial communities interact, it may be possible to improve existing therapies or to develop new therapeutic strategies altogether.

Phillips said he looks forward to continuing his research at Texas Tech. His lab is developing a follow-up study that he hopes will collect enough information to create accurate predictive models. They also are working on a study exploring how a persons location in the U.S. shapes differences in chronic wound microbiomes.

Texas Tech provides good support for research and is continually working for growth, Phillips said. My research, like that of most others, has been generally enhanced by the academic freedom provided at the university. The Natural Science Research Laboratory is a premier Natural History Collection, and the samples archived at the Genetic Resources Collection have allowed me to design studies such as this one that would otherwise not have been possible. The hard work and creativity of doctoral student Craig Tipton were essential to the success of this project, as was collaboration with the laboratories ofNicole Phillipsat UNTHSC andKendra Rumbaughat TTUHSC, ProfessorTodd Littlein the Texas TechCollege of Education, the SWRWCC and the NSRL.

The team of researchers included:

To read the complete study, visit the PLOS Pathogens website.

(News release from Texas Tech University)

Original post:
Researchers say genetics may determine wound infection and healing - KLBK | KAMC | EverythingLubbock.com

Read More...

Genetic diabetes test effective in people of Indian heritage – Medical News Today

June 26th, 2020 4:53 pm

There are concerns that doctors could misdiagnose diabetes in India due to higher rates of type 2 diabetes in younger and slimmer people. A new study has shown that an existing genetic test could accurately diagnose diabetes in people of Indian heritage.

Although people often use the word diabetes to describe one condition, there are actually two different types of diabetes.

Type 1 diabetes is an autoimmune disease that causes damage to the beta cells in the pancreas that produce insulin. A lack of insulin is the primary characteristic of type 1 diabetes.

Treatment involves regular injections with insulin.

Type 2 diabetes is the more common form of diabetes. It is not an autoimmune condition and typically involves resistance to rather than a lack of insulin.

Treatments include medications to increase insulin sensitivity and lifestyle changes, such as following a healthful diet.

Previously, experts have associated the two forms with different age groups:

However, this view is shifting due to rising rates of childhood obesity and recent findings that type 1 diabetes can occur later in life.

This has led to concerns regarding misdiagnosis, particularly in Indian populations, where there is a higher prevalence of type 2 diabetes in younger and slimmer people.

Furthermore, scientists have carried out most research on type 1 diabetes in European populations, which means existing diagnostic tools may not apply.

Misdiagnosis in diabetes is a growing concern. One recent study of 583 participants from the population-based Exeter Diabetes Alliance for Research in England (DARE) in the United Kingdom found that almost 40% of adults with type 1 diabetes did not receive a correct initial diagnosis and received treatment for type 2 diabetes.

Diagnosing diabetes accurately is vital because administering the wrong treatment could have severe consequences, such as diabetic ketoacidosis.

Diagnosing the right diabetes type is an increasingly difficult challenge for clinicians, as we now know that type 1 diabetes can occur at any age. This task is even harder in India, as more cases of type 2 diabetes occur in people with low BMI, explains Dr. Richard Oram of the Institute of Biomedical and Clinical Science at the University of Exeter Medical School in the U.K.

A collaborative study between researchers in Hyderabad in India and the University of Exeter has looked at the effectiveness of current genetic risk scores for diagnosing type 1 diabetes in Indian populations.

The authors published the study in Scientific Reports.

The researchers assessed whether the genetic risk score can effectively discriminate between type 1 and type 2 diabetes in people from Pune in the west of India, who were of Indo-European ancestry.

They analyzed 262 people with confirmed type 1 diabetes, 345 people with type 2 diabetes, and a control group of 324 people who did not have diabetes. They then compared the outcomes with those of European people from the Wellcome Trust Case Control Consortium study.

The researchers found that the current genetic risk score is effective at diagnosing diabetes in Indian populations, even though the original data were from European people.

However, the team also identified new genetic differences between European and Indian populations, making the test more accurate for Indian people.

They found nine new genetic variants (single-nucleotide polymorphisms, or SNPs) that correlate with type 1 diabetes in both groups that doctors could use to predict the onset of the disease in Indian people.

Its interesting to note that different SNPs are more abundant among Indian and European patients. This opens up the possibility that environmental factors might be interacting with these SNPs to cause the disease, explains Dr.G. R Chandak, the scientist leading the study at the CSIR-Centre for Cellular and Molecular Biology in Hyderabad, India.

The results are good news for doctors using this score to diagnose people in India.

We look forward to using this test in diabetic patients from different parts of India, where the physical characteristics of diabetic patients differ from the standard description.

Dr. Chittaranjan Yajnik, KEM Hospital & Research Centre in Pune, India

However, India is a vast country with a lot of genetic diversity, so researchers must also validate this test in other ethnic groups.

Over time, the team hopes to develop a genetic test for type 1 diabetes specific to people with Indian ancestry.

A combined approach, including both genetic risk scores and clinical features, such as auto-antibodies indicative of type 1 diabetes), will be the most effective way to diagnose the disease.

The rest is here:
Genetic diabetes test effective in people of Indian heritage - Medical News Today

Read More...

Scientists reverse Parkinsons disease in mice by tweaking the genetic code of non-neuronal brain cells – Firstpost

June 26th, 2020 4:53 pm

FP TrendingJun 26, 2020 13:48:02 IST

Scientists are developing a one-off treatment that appears to permanently cure Parkinson's disease in mice.

The results of the study, conducted by researchers from the University of California, were published in the scientific journal Nature.

According to study authors, they hope that the same approach can be used to treat a wide range of neurodegenerative conditions in human beings.

According to a report in IFL Science, Parkinson's and other types of dementia occur when neurons become damaged and die. Scientists have spent decades trying to come up with treatments to protect the brain cells or generate new ones to replace the ones that are lost.

Study authors have now been able to achieve this by altering a single gene.

The report mentions that researchers tweaked the genetic code of non-neuronal brain cells called astrocytes in petri dish. The astrocytes facilitate communication throughout the brain by producing a protein called PTB which ensures that they do not transform into neurons.

When researchers blocked the production of PTB, the astrocytes transformed into neurons.

Left: mouse astrocytes (green) before reprogramming; Right: neurons (red) induced from mouse astrocytes after reprogramming with PTB antisense oligonucleotide treatment. Image credit: University of California

According to a statement released by the University of California, lead author Xiang-Dong Fu said, "Researchers around the world have tried many ways to generate neurons in the lab, using stem cells and other means, so we can study them better, as well as to use them to replace lost neurons in neurodegenerative diseases," adding, "The fact that we could produce so many neurons in such a relatively easy way came as a big surprise.

As per a report in Eurekalert, researchers developed a noninfectious virus that carries an antisense oligonucleotide sequence and administered it directly to the mouse's midbrain, which is responsible for regulating motor control and reward behaviours and the part of the brain that loses dopamine-producing neurons in Parkinson's disease. A control group of mice received a mock treatment.

According to the report, in the mice that were properly treated, a small subset of astrocytes converted to neurons, increasing the number of neurons by approximately 30 percent. Researchers also found that Dopamine levels were restored to a level comparable to that in normal mice. They found that the neurons grew and sent their processes into other parts of the brain and the mice returned to normal within three months after a single treatment.

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

Originally posted here:
Scientists reverse Parkinsons disease in mice by tweaking the genetic code of non-neuronal brain cells - Firstpost

Read More...

Ground-breaking research uncovers genetic causes of rare diseases – University News: The University of Western Australia

June 26th, 2020 4:53 pm

A research program pioneering the use of whole genome sequencing has diagnosed hundreds of patients with rare diseases and discovered new genetic causes of disease.

The international study, published today in Nature, included a researcher and haematologist from The University of Western Australia and PathWest.

The study focused on patients with rare disease in the UK National Health Service. Professor Wendy Erber, from UWAs Faculty of Health and Medical Sciences and a PathWest haematologist, provided key input through her analysis of the blood cells and blood count results.

Professor Erbers analysis, combined with sophisticated new bioinformatic computing tools and software developed specifically for the project, has provided ground-breaking insight into the genetic basis of rare diseases.

This integrated approach was critical to the analysis and understanding of such large, complex and unique sets of biological data for patients with these rare conditions, Professor Erber said.

The researchers, led by the UK National Institute for Health Research BioResource and Genomics England, studied the entire genomes, or 3.2 billion DNA letters, of almost 10,000 patients with rare diseases that affect the blood, the immune system and other tissues.

They identified genetic changes causing some known rare diseases, and, described some completely new genetic diseases. Although individual rare diseases affect a very small proportion of the population, there are thousands of rare diseases and, together, they affect more than one million people in Australia.

The sophisticated analysis identified 95 genes very likely to cause rare diseases, including unexplained bleeding disorders and immune deficiency syndromes that lead to the inability of the body to fight infections.

Study participants now know the cause of their clinical problems and finally have a confirmed diagnosis, Professor Erber said.

Patients with these rare diseases can now receive the most appropriate treatment for their condition. This is already leading to improved patient care.

The genetic results from the research are now being translated into clinical practice and will be rolled out as a standard of care throughout the UKs National Health Service.

This type of research is incredibly important to combat rare genetic diseases. I hope the findings will have an influence on the standard of care in Australia, Professor Erber said.

The benefits will include quicker diagnosis for patients, improved understanding of the reasons they suffer from disease, improved provision of treatment and reduced costs for health services.

Professor Wendy Erber (UWA School of Biomedical Sciences) 08 6457 2325 / 0418 610 600Nicholas Smith (UWA Media Officer)08 6488 1888 / 0411 644 492

View original post here:
Ground-breaking research uncovers genetic causes of rare diseases - University News: The University of Western Australia

Read More...

I Just Started Crying: Redondo Beach Baby Diagnosed With Rare Genetic Disease That Will Cost Millions To Treat – CBS Los Angeles

June 26th, 2020 4:52 pm

REDONDO BEACH (CBSLA) Rhys Devine was born in the pandemic a quarantine baby full of love and the apple of her parents eyes.

She is happy, Ceri Devine, Rhys mother, said. She is smiley.

But a few months after she was born, her parents noticed something seemed off.

Everyone kept telling me, Its nothing. Shes just behind on her development, and I kind of just, Ceri said. I felt like there was something wrong.

Rhys was struggling to hold herself upright, so her parents took her to the doctor.

The pediatrician had us come in right away, and she examined her and that was when she expressed her concern that it might be spinal muscular atrophy, Ceri said. I remember googling it on my way home from the pediatrician and the first thing that came up was, you know, most infants diagnosed with SMA do not live past two years of age, and I just started crying.

Spinal Muscular Atrophy Type 1 is a devastating genetic disease in infants that causes their muscles to waste away, eventually making it difficult to do things like move, eat and even breathe.

These infants would then become progressively weaker and weaker and weaker until they cant breathe, Dr. Perry Shieh, UCLA professor of neurology, said. The parents who choose to keep them alive they would actually have to get a ventilator.

The Devines doctors told them about two brand new, potentially lifesaving drugs, but there was a catch.

He gave us some hope telling us that the Spinraza and the Zolgensma were options to help have Rhys potentially live into retirement age, Rory Devine, Rhys father, said. But then he also told us that the cost of one dose of Zolgensma is $2.1 million dollars.

The family is determined to give Rhys a fighting chance. To help, friends started a GoFundMe page to help cover the enormous costs of care.

Doctors said now its a race against time.

This is like a down hill, and you cant actually climb back up the hill, Shieh said. So what we like want to do is emphasize that its important to be able to identify our patients as early as possible.

On Wednesday, California started screening all newborn babies for SMA before they leave the hospital, a move doctors said would be a game changer in guaranteeing treatment.

As for the Devine family, they have a long road of treatments ahead and have created a website where they will be documenting their journey.

Link:
I Just Started Crying: Redondo Beach Baby Diagnosed With Rare Genetic Disease That Will Cost Millions To Treat - CBS Los Angeles

Read More...

Inherited Genetic Mutations Are Common in Young Adults With Early-Onset Cancer – Cancer Health Treatment News

June 26th, 2020 4:52 pm

Adults under 40 who develop cancers that are rare for their age bracket have a high rate of inherited gene mutations associated with cancer.

People with inherited genetic mutations who develop such cancersknown as early-onset cancersare more likely to develop new malignancies unrelated to their first cancer and to experience other health complications.

The most common early-onset cancers, which by definition are rare malignancies among younger adults, are breast, colon, pancreas kidney, prostate and ovarian cancer. These are distinct from other types of cancer that are more commonly seen among young adults, such as sarcoma and brain cancer.

Thus, the new findings from a recent study, presented this week at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, have important implications for how younger adults with cancer might receive genetic counseling that could inform their treatment as well as their ongoing monitoring as they progress through life.

This study supports a role for genetic testing irrespective of tumor types, Zsofia Stadler, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said at an AACR press briefing.

Stadler and her colleagues assessed inherited genetic mutations among 1,201 young adults diagnosed with cancer at Sloan Kettering between 2015 and 2019, looking specifically for up to 88 genes known to be linked to a higher risk of cancer.

Eight hundred seventy-seven of the participants had early-onset cancermost commonly colorectal, breast, kidney, pancreatic and ovarian cancer; 324 had young-adult cancers that are common in this age groupmost commonly sarcoma and brain, testicular and thyroid cancer.

The researchers found that 21% of those with early-onset cancers and 13% of those with young-adult cancers had inherited genetic mutations (also known as germline mutations).

Among people with early-onset cancers, BRCA gene mutations and those associated with Lynch syndrome (the most common cause of hereditary colon cancer) were seen most often. Among those with young-adult cancers, inherited TP53 mutations were more common; these are characteristic of Li-Fraumeni syndrome, which is associated with childhood cancers.

Although they only represent about 4% of all cancers, young adults with cancer, defined as those diagnosed with cancer between the ages of 18 and 39, face unique challenges, said Stadler. Identifying whether a young patients cancer occurred in the setting of an inherited cancer predisposition syndrome is important as it can result in a substantial change in clinical management, such as increased cancer surveillance aimed at early detection and risk-reducing surgery to prevent new cancers and may even have reproductive implications for young families.

To read the study abstract, click here.

To read a press release about the study, click here.

Follow this link:
Inherited Genetic Mutations Are Common in Young Adults With Early-Onset Cancer - Cancer Health Treatment News

Read More...

Rawlins native returns home to practice medicine | Hospitality & Tourism – Wyoming Business Report

June 26th, 2020 4:51 pm

RAWLINS The MHCC Family Practice Clinic would like to introduce their newest provider, Dr. Gary Mikesell, D.O.

Born and raised in Rawlins, Mikesell began his medical career in 1982 with Memorial Hospital of Carbon County where he worked as a patient transporter. After graduating from Rawlins High School, he attended the University of Wyoming for a year before completing a two year mission with Church of Jesus Christ of Latter-Day Saints. Mikesell then returned to the University of Wyoming where he majored in Microbiology. After transferring to Brigham Young University, he graduated with a degree in Microbiology and Pre-Med. He was then accepted to medical school at Western University/College of Osteopathic Medicine of the Pacific in southern California. Dr. Mikesell completed medical school in 1996.

Dr. Mikesell has built his career on family practice and urgent care, with over 21 years experience in both. In addition, he also has a strong interest in preventative medicine and sports medicine. He is trained to do spinal and musculoskeletal manipulations to help with back, neck and musculoskeletal pain. Dr. Mikesell also has a Buprenorphine Waiver which allows him to treat patients with narcotic addictions.

Dr. Mikesell enjoys hunting, fishing, camping and taking vacations with his wife, Leticia, and four children. He is very involved in the church and has a strong faith in God. Starting today, Dr. Mikesell will begin seeing patients at the MHCC Family Practice Clinic. Contact the clinic at 307-324-8494 to schedule an appointment.

Here is the original post:
Rawlins native returns home to practice medicine | Hospitality & Tourism - Wyoming Business Report

Read More...

J&J presents Significant Progress in Myopia Screening and Education in APAC – BSA bureau

June 26th, 2020 4:51 pm

Nearly 35,000 Children in the Asia Pacific Receive Eye Exams with Myopia Screening

Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, has announced new clinical research on Myopia progression in children and detailed significant child Myopia screening and education progress in the Asia Pacific region. The clinical research and public health programs are part of the comprehensive Myopia research collaboration with the Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC) launched in April 2019.

Current estimates show that by 2050 half of the worlds population is expected to be myopic, with a disproportionate impact on our children, said Xiao-Yu Song, MD, PhD, Global Head of Research and Development, Johnson & Johnson Vision Care, Inc. Through close collaborations with SERI, SNEC, and other aligned public health groups, we are helping to address this crisis by building a better understanding of the science and biology behind Myopia and developing comprehensive programs to address and treat the disease.

Researchers for the collaboration presented some of its first clinical research findings at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The collaborations five studies at ARVO focus on new techniques and practices to better predict Myopia progression and vision impairment, significant challenges for eye care professionals when so much of Myopia disease progression is still to be understood.

The research team presented new findings on Myopia progression from one of the largest clinical research studies with children. In the study of 674 myopic children aged seven to 10-years old over two-years, the authors found that a childs prior year Myopia progression correlates with immediate subsequent year progression. That is, the investigators found that children with slow Myopia progression during the first year generally had slow progression in year two, while children with fast Myopia progression in year one generally had fast progression in year two.

However, the authors report that year-over-year progression as a single factor does not fully predict long-term Myopia progression and that a childs age and parental Myopia are important additional variables to consider in choosing whether to treat a childs progression.

Globally, for parents of children with Myopia, and eye care professionals, an important takeaway is the need for myopic patients to receive regular annual check-ups, said study lead author Noel Brennan, PhD, Global Lead, Myopia Control, Johnson & Johnson Vision. While Myopia progression rates will naturally be followed from year-to-year, it is also important that eye care professionals consider the age of Myopia onset and parental Myopia.

The author presentation and study, Annual Myopia Progression and Subsequent Year Progression in Singaporean Children, is published on ARVOLearn as part of ARVOs virtual congress.

MYOPIA SCREENING AND EDUCATION PROGRAM PROGRESS IN ASIA PACIFIC

Since the formal launch of the collaboration just over a year ago, Johnson & Johnson Vision, Johnson & Johnson Global Community Impact, SERI, and SNEC have also been working to advance critical Myopia screening and education programs in the Asia Pacific region where current prevalence rates among young people are as high as 80 to 97 percent in urban areas in East Asia and Singapore.

In China, among children ages six to 18, Myopia prevalence rises from less than 10 to 80 percent. In Singapore, one in two children develop Myopia by the age of 12, and 75 percent of teenagers are myopic and rely on glasses.Left unchecked, in some patients, Myopia can lead to blindness or other eye health conditions that can severely impact vision and overall well-being.

Tackling the Myopia epidemic globally requires a comprehensive approach that includes critical education and screening campaigns, said Dr. Song. We are very pleased by the progress of the public health programs in Asia being supported by the collaboration, and that young children are receiving comprehensive eye exams and necessary referrals when diagnosed with Myopia. We look forward to continued progress as we learn to manage these initiatives through the COVID-19 pandemic.

Working through the Fred Hollows Foundation, and Chinas Yunnan Provincial Health Commission and Provincial Education Department, the collaboration launched its three-and-a-half-year Child Eye-Health Program in Chinas Yunnan Province in August 2019. The program trains ophthalmologists, refractionists, community health workers, and teachers in screening techniques and supports student screening programs. In the second half of 2019, the collaboration has already supported the screening of nearly 30,000 primary school students in Yunnan Province, and provided eye health and myopia prevention knowledge to almost 20,000 students.

The collaboration has also become a strategic partner with the Ministry of Educations Research Center for Prevention, Control and Diagnosis of Myopia to support the improvement of Myopia public awareness and the development of Myopia awareness education tools. In addition, the collaboration is working with the Beijing Preventative Medicine Association and Beijing CDC on a Myopia school screening program that is seeking to examine 4,000 students from September 2019 to the end of 2020.

Read more:
J&J presents Significant Progress in Myopia Screening and Education in APAC - BSA bureau

Read More...

Can people without symptoms spread COVID-19? Five questions answered about how the virus is spread | Opinion – pennlive.com

June 26th, 2020 4:51 pm

Can people spread the coronavirus if they don't have symptoms? 5 questions answered about asymptomatic COVID-19 Screening for symptoms can catch some cases of COVID-19, but about people who are infected but not showing any symptoms? AP Photo/John Raoux Monica Gandhi, University of California, San Francisco

Screening for symptoms of COVID-19 and self-quarantine are good at preventing sick people from spreading the coronavirus. But more and more evidence is suggesting that people without symptoms are spreading the virus too. Monica Gandhi, an infectious diseases physician and researcher at the University of California, San Francisco, explains what is known about asymptomatic spread and why she thinks it may be a big part of what is driving the pandemic.

SARS-CoV-2 the virus that causes COVID-19 can produce a range of clinical manifestations.

Some people who are infected never develop any symptoms at all. These patients are considered true asymptomatic cases.

When people do get sick from the coronavirus, it takes on average five days and as many as two weeks to develop symptoms that can range from very mild to extremely dangerous. The time between initial infection and the first symptoms is called the pre-symptomatic phase.

As an infectious disease physician, when I hear about asymptomatic spread of SARS-CoV-2, I think of a person who doesnt have symptoms at the moment they give the virus to someone else. It doesnt matter whether they are a true asymptomatic case or just pre-symptomatic; the public health risk is the same.

Estimates of the proportion of true asymptomatic cases those who are infected and never develop symptoms range from 18% to over 80%. The reasons for the huge range in estimates are still unclear, but some studies are better than others.

The most accurate way to determine the rate of asymptomatic cases is to test people regardless of whether or not they have symptoms an approach called universal mass testing and track them over time to see if they develop symptoms later. A recent mass testing campaign in San Francisco found that 53% of infected patients were asymptomatic when first tested and 42% stayed asymptomatic over the next two weeks.

Another recent paper compared the evidence from 16 studies and estimated the overall rate of asymptomatic infection to be 40%-45%. This is in line with the San Francisco finding, but the studies sampled were of various quality and size and likely include some pre-symptomatic cases.

Though none of these studies is perfect, a lot of evidence supports a true asymptomatic rate of around 40%, plus some addition fraction of patients who are pre-symptomatic.

Compared to most other viral infections, SARS-CoV-2 produces an unusually high level of viral particles in the upper respiratory tract specifically the nose and mouth. When those viral particles escape into the environment, that is called viral shedding.

Researchers have found that pre-symptomatic people shed the virus at an extremely high rate, similar to the seasonal flu. But people with the flu dont normally shed virus until they have symptoms.

The location of the shedding is also important. SARS-CoV the virus that caused the SARS epidemic in 2003 does not shed very much from the nose and mouth. It replicates deep in the lungs. Since SARS-CoV-2 is present in high numbers in a persons nose and mouth, it is that much easier for the virus to escape into the environment.

When people cough or talk, they spray droplets of saliva and mucus into the air. Since SARS-CoV-2 sheds so heavily in the nose and mouth, these droplets are likely how people without symptoms are spreading the virus.

Public health experts dont know exactly how much spread is caused by asymptomatic or pre-symptomatic patients. But there are some telling hints that it is a major driver of this pandemic.

An early modeling estimate suggested that 80% of infections could be attributed to spread from undocumented cases. Presumably the undocumented patients were asymptomatic or had only extremely mild symptoms. Though interesting, the researchers made a lot of assumptions in that model so it is hard to judge the accuracy of that prediction.

A study looking at outbreaks in Ningbo, China, found that people without symptoms spread the virus as easily as those with symptoms. If half of all infected people are without symptoms at any point in time, and those people can transmit SARS-CoV-2 as easily as symptomatic patients, it is safe to assume a huge percentage of spread comes from people without symptoms.

Even without knowing the exact numbers, the Centers for Disease Control and Prevention believes that transmission from people without symptoms is a major contributor to the rapid spread of SARS-CoV-2 around the world.

Any time a virus can be spread by people without symptoms, you have to turn to preventative measures.

Social distancing measures and lockdowns work, but have large economic and social repercussions. These were necessary when epidemiologists didnt know how the virus was spreading, but now we know it sheds at high quantities from the upper respiratory tract.

This means that universal mask wearing is best tool to limit transmission, and there is evidence to back that idea up.

On April 3, the CDC recommended that all members of the public wear facial coverings when outside of the house and around others. The World Health Organization finally followed suit and recommended universal public masking on June 5.

At this point, no one knows exactly how many cases of COVID-19 are from asymptomatic spread. But I and many other infectious diseases researchers are convinced that it is playing a major role in this pandemic. Wearing a mask and practicing social distancing can prevent asymptomatic spread and help reduce the harm from this dangerous virus until we get a vaccine.

[You need to understand the coronavirus pandemic, and we can help. Read The Conversations newsletter.]

Monica Gandhi, Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
Can people without symptoms spread COVID-19? Five questions answered about how the virus is spread | Opinion - pennlive.com

Read More...

Medical Wellness Market Demand (2020-2027) | Covering Products, Financial Information, Developments, SWOT Analysis And Strategies | Market Expertz -…

June 26th, 2020 4:51 pm

A research report on the Medical Wellness market has been presented by Market Expertz, offering an extensive analysis of the Global Medical Wellness Market where the readers can benefit from the complete market study with all the relevant information about the market.

This is the latest report covering the current COVID-19 scenario. The coronavirus pandemic has greatly affected every aspect of life worldwide. This has brought along various changes in market conditions.

The rapidly changing market scenario and the initial and future assessment of the impact are covered in the research report. The report discusses all the major aspects of the market with expert opinions on the current status along with historical data.

Get a Free Sample Copy of the Medical Wellness Market Report with the Latest Industry [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/45479

Leading Medical Wellness manufacturers/companies operating at both regional and global levels:

Massage EnvySteiner Leisure LimitedWorld GymFitness WorldUniversal CompaniesBeauty FarmVLCC Wellness CenterNanjing ZhaohuiEdge Systems LLCHEALING HOTELS OF THE WORLDGolds Gym International

This report consists of reliable data on the investment opportunities, market dynamics, competition analysis, major market players, basic industry facts, important figures, prices, sales, revenues, gross margins, market shares, key business strategies, top regions, among others.

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/45479

Global Medical Wellness Market Segmentation

This market has been segmented into Types, Applications, and Regions. The growth calculation of each segment provides an accurate forecast of the sales in terms of volume and revenue for the period 2016-2027. This study can help readers expand their business by targeting qualified niche markets. Market share data is also available on the regional and global levels.

In market segmentation by types of Medical Wellness, the report covers-

Complementary and Alternative MedicineBeauty Care and Anti-AgingPreventative & Personalized Medicine and Public HealthHealthy Eating, Nutrition & Weight LossRejuvenationOther

In market segmentation by applications of the Medical Wellness, the report covers the following uses-

FranchiseCompany Owned Outlets

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Medical Wellness sector and can help companies in deciphering the optimum business move to reach their desired business goals.

To Obtain All-Inclusive Information and Accurate Forecast of the Medical Wellness Market, Request a Custom [emailprotected] https://www.marketexpertz.com/customization-form/45479

Global Medical Wellness Market Regions Level Analysis:

Geographically, regions covered in the research report are North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The analysts provide competitive analysis for each region and competitor separately.

Regional analysis is a major part of this report. It focuses on the sales of the Medical Wellness on the regional level. The data provides the readers with a detailed and extensive country-wise volume analysis and region-wise market size analysis of the global Medical Wellness market.

It offers an in-depth assessment of the growth aspects of the market in the key countries. The competitive landscape chapter of the global Medical Wellness market report delivers key information regarding the market players including the company overview, company profiles, total revenue, market potential, growth prospects, global presence, sales and revenue, market share, production sites and facilities, product offerings, latest developments and innovations and key strategies adopted.

Key Coverage:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast by Types6. Global Market Analysis and Forecast by Applications7. Global Market Analysis and Forecast by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/medical-wellness-market

To summarize, the global Medical Wellness market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

Read the original here:
Medical Wellness Market Demand (2020-2027) | Covering Products, Financial Information, Developments, SWOT Analysis And Strategies | Market Expertz -...

Read More...

Page 480«..1020..479480481482..490500..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick